Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.

"Competing interests AS, VK, KK, SC, PU and CK are employed at the Roche Innovation Center Zurich, Schlieren, Switzerland and JE is employed at the Roche Innovation Center Munich, Penzberg, Germany. These authors also declare patents and ownership of Roche stock. DD is employed at Genentech Inc., South San Francisco, CA. MSu has received industry research support from Amgen, Gilead, Miltenyi Biotec, Morphosys, Roche, and Seattle Genetics, and has served as a consultant/advisor to Amgen, BMS, Celgene, Gilead, Pfizer, Novartis, and Roche. She sits on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics, and serves on the speakers’ bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer. GH, ASN and MSu declare patents together with Roche. DN, NP, MSp, AL and VB declare no relevant competing interests."

"Funding Open Access funding enabled and organized by Projekt DEAL."